Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men

被引:347
作者
Antoniucci, Diana M.
Yamashita, Takeyoshi
Portale, Anthony A.
机构
[1] Univ Calif San Francisco, Div Pediat Neurol, Dept Pediat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA
[3] Kirin Brewery Co Ltd, Pharmaceut Res Lab, Takasaki, Gumma 3701295, Japan
关键词
D O I
10.1210/jc.2006-0021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Fibroblast growth factor 23 (FGF-23) is important in the regulation of phosphorus and vitamin D metabolism. States of excess circulating FGF-23 are associated with renal phosphate wasting and inappropriately low serum 1,25-dihydroxyvitamin D [1,25(OH)(2)D] concentrations. Conversely, states of absent or biologically inactive circulating FGF-23 are associated with increased serum phosphorus and 1,25(OH)(2)D concentrations. Restriction of the dietary intake of phosphorus increases renal phosphate reabsorption and 1,25(OH)(2)D production, whereas the opposite occurs when dietary phosphorus is supplemented. Objective: We sought to determine whether serum FGF-23 concentration is regulated by dietary phosphorus and thereby mediates the physiological response of serum 1,25(OH)(2)D to changes in dietary phosphorus. Design, Setting, and Participants: We studied 13 healthy men as inpatients during a 4-wk dietary phosphorus intervention study. Intervention: Subjects consumed a constant diet that provided 500 mg of phosphorus per day, which was supplemented to achieve three phosphorus intakes, each of 9 d: 1) control = 1500 mg/d; 2) supplemented = 2300 mg/d; 3) restricted = 625 mg/d. Intakes of calcium, sodium, potassium, magnesium, and energy were constant. Main Outcome Measure: Serum FGF-23, 1,25(OH) 2D, phosphorus, and calcium concentrations were measured. Results: Serum FGF- 23 concentrations decreased significantly from 30.7 +/- 8.7 pg/ml during phosphorus supplementation to 19.6 +/- 7.0 pg/ml during phosphorus restriction. Serum 1,25(OH)(2)D concentrations increased significantly from 29 +/- 10 pg/ml (75 +/- 26 pmol/liter) during phosphorus supplementation to 40 +/- 16 pg/ml (104 +/- 42 pmol/liter) during phosphorus restriction (P < 0.001). Serum 1,25(OH)(2)D concentrations varied inversely with those of serum FGF-23 (r = -0.67, P < 0.001). Conclusions: We conclude that in healthy men, changes in dietary phosphorus within the physiological range of intakes regulate serum FGF-23 concentrations and suggest that dietary phosphorus regulation of 1,25(OH)(2)D production is mediated, at least in part, by changes in circulating FGF-23.
引用
收藏
页码:3144 / 3149
页数:6
相关论文
共 45 条
[1]   A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis [J].
Araya, K ;
Fukumoto, S ;
Backenroth, R ;
Takeuchi, Y ;
Nakayama, K ;
Ito, N ;
Yoshii, N ;
Yamazaki, Y ;
Yamashita, T ;
Silver, J ;
Igarashi, T ;
Fujita, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5523-5527
[2]   Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders [J].
Bai, XY ;
Miao, DS ;
Li, JR ;
Goltzman, D ;
Karaplis, AC .
ENDOCRINOLOGY, 2004, 145 (11) :5269-5279
[3]   An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia [J].
Benet-Pagès, A ;
Orlik, P ;
Strom, TM ;
Lorenz-Depiereux, B .
HUMAN MOLECULAR GENETICS, 2005, 14 (03) :385-390
[4]   SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis [J].
Bergwitz, C ;
Roslin, NM ;
Tieder, M ;
Loredo-Osti, JC ;
Bastepe, M ;
Abu-Zahra, H ;
Frappier, D ;
Burkett, K ;
Carpenter, O ;
Anderson, D ;
Garabédian, M ;
Sermet, I ;
Fujiwara, TM ;
Morgan, K ;
Tenenhouse, HS ;
Jüppner, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 78 (02) :179-192
[5]   INTERACTIONS BETWEEN VITAMIN-D DEFICIENCY AND PHOSPHORUS DEPLETION IN THE RAT [J].
BRAUTBAR, N ;
WALLING, MW ;
COBURN, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 63 (02) :335-341
[6]  
*DEP HLTH HUM SERV, 2002, NATL CTR HLTH STAT S, V11, P74
[7]   Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder [J].
Econs, MJ ;
McEnery, PT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :674-681
[8]   Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men [J].
Ferrari, SL ;
Bonjour, JP ;
Rizzoli, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1519-1524
[9]  
Fiske CH, 1925, J BIOL CHEM, V66, P375
[10]   A GENE (PEX) WITH HOMOLOGIES TO ENDOPEPTIDASES IS MUTATED IN PATIENTS WITH X-LINKED HYPOPHOSPHATEMIC RICKETS [J].
FRANCIS, F ;
HENNIG, S ;
KORN, B ;
REINHARDT, R ;
DEJONG, P ;
POUSTKA, A ;
LEHRACH, H ;
ROWE, PSN ;
GOULDING, JN ;
SUMMERFIELD, T ;
MOUNTFORD, R ;
READ, AP ;
POPOWSKA, E ;
PRONICKA, E ;
DAVIES, KE ;
ORIORDAN, JLH ;
ECONS, MJ ;
NESBITT, T ;
DREZNER, MK ;
OUDET, C ;
PANNETIER, S ;
HANAUER, A ;
STROM, TM ;
MEINDL, A ;
LORENZ, B ;
CAGNOLI, M ;
MOHNIKE, KL ;
MURKEN, J ;
MEITINGER, T .
NATURE GENETICS, 1995, 11 (02) :130-136